Compare Amylx Pharmaceuticals Inc (AMLX) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Nuscale Power Corporation — how do they compare? Amylx Pharmaceuticals Inc trades at $23.67 (market cap $2.64B), while Nuscale Power Corporation trades at $9.78 (market cap $4.06B). The key difference: Nuscale Power Corporation is the larger of the two by market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Nuscale Power Corporation nearer its low. Which is the better fit depends on your goals.
| AMLX | SMR | |
|---|---|---|
Market Cap | $2.64B | $4.06B |
Sector | Health | Utilities |
52-Week High | $24.19 | $53.43 |
52-Week Low | $7.82 | $7.59 |
Enterprise Value | $2.39B | $2.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
NuScale Power (SMR) trades at $9.76, up 6.32% in the last session, with a bullish technical signal from moving averages. The company reported a net loss of $355.79 million in 2025 on revenue of $31.48 million, with negative margins, while analyst consensus is a Buy with a $10.50 price target. Recent news highlights regulatory progress and AI-driven power demand as growth catalysts.
Outlook hinges on commercial deployment of small modular reactors, offering high upside if execution succeeds, but risks include persistent losses, revenue volatility, and project delays. The stock presents speculative growth potential amid significant operational and financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
